

**Errata – FDA Briefing Document**  
**Peripheral and Central Nervous System Drugs Advisory Committee Meeting**  
**October 14, 2009**  
**Amaya (fampridine), manufactured by Acorda Pharmaceuticals, Inc.**

**1. Page 11, Table 1:**

*Table 1: FDA analyses of Study MS-F203*

Study MS-F203	Placebo (n=72)	Fampridine (n=224)	p value
Baseline walking speed (ft/sec)	2.12	2.14	0.88
Visit 6 Walking speed (ft/sec)	2.16	2.35	0.19
Walking speed change Visit 6 vs. baseline (ft/sec)	0.05	.21	0.03
Walking speed change Visit 6 vs. baseline (%)	5.58	10.90	0.24
Walking speed on drug (average)	2.16	2.34	0.17
Walking speed change (ft/sec) on drug (average) vs. baseline	0.10	0.28	0.0004
Walking speed change (%) on drug (average) vs. baseline	4.71	13.63	0.0003
MSW12 change on drug (average) vs. baseline	0.62	-2.72	0.084
MSW12 change Visit 6 vs. baseline	3.59	-1.56	0.063
SGI change on drug vs. baseline	-0.1967	-0.0045	0.12
LEMMT change on drug vs. baseline	0.04	0.13	0.003
Ashworth change on drug vs. baseline	-0.07	-0.16	0.021

**Change to:**

*Table 1: FDA analyses of Study MS-F-203*

Study MS-F203	Placebo (n=72)	Fampridine (n=224)	p-value
Baseline walking speed (ft/sec)	2.12	2.14	0.88
Visit 6 Walking speed (ft/sec)	2.16	2.35	0.19
Walking speed change Visit 6 vs. baseline (ft/sec)	0.05	0.21	0.03
Walking speed change Visit 6 vs. baseline (%)	5.58	10.90	0.24
Walking speed on drug (average)	2.16	2.34	0.17
Walking speed change (ft/sec) on drug (average) vs. baseline	0.10	0.28	0.0004
Walking speed change (%) on drug (average) vs. baseline	4.71	13.63	0.0003
MSWS-12 change on drug (average) vs. baseline	0.62	-2.72	0.084
MSWS-12 change Visit 6 vs. baseline	<b>5.05</b>	<b>-0.04</b>	<b>0.0604</b>
SGI change on drug vs. baseline	-0.1967	-0.0045	0.12
LEMMT change on drug vs. baseline	0.04	0.13	0.003
Ashworth change on drug vs. baseline	-0.07	-0.16	0.021

2. Page 13, Table 2:

*Table 2: FDA analyses of Study MS-F204*

Study MS-F204	Placebo	Fampridine	p value
Baseline walking speed (ft/sec)	2.28	2.21	0.5463
Visit 6 Walking speed (ft/sec)	2.39	2.42	0.7284
Walking speed change Visit 6 vs. baseline (ft/sec)	.11	.22	0.0425
Walking speed change Visit 6 vs. baseline (%)	4.87%	10.64%	0.0392
Walking speed on drug (average)	2.37	2.41	0.7135
Walking speed change (ft/sec) on drug (average) vs. baseline	0.17	0.29	0.0089
Walking speed change (%) on drug (average) vs. baseline	7.67%	13.99%	0.0072
MSW12 change on drug (average) vs. baseline	0.73	-2.62	0.0213
MSW12 change Visit 6 vs. baseline	0.72	-3.12	0.0264
SGI change on drug vs. baseline	-0.04	0.09	0.1939
LEMMT change on drug vs. baseline	0.04	0.09	.1059
Ashworth change on drug vs. baseline	-0.06	-0.18	0.0153

**Change to: Table 2: FDA analyses of Study MS-F-204**

Study MS-F204	Placebo N=118	Fampridine N=119	p-value
Baseline walking speed (ft/sec)	2.28	2.21	0.5463
Visit 6 Walking speed (ft/sec)	2.39	2.42	0.7284
Walking speed change Visit 6 vs. baseline (ft/sec)	0.11	<b>0.21</b>	<b>0.0729</b>
Walking speed change Visit 6 vs. baseline (%)	<b>4.83</b>	<b>10.18</b>	<b>0.0552</b>
Walking speed on drug (average)	2.37	2.41	0.7135
Walking speed change (ft/sec) on drug (average) vs. baseline	0.17	0.29	0.0089
Walking speed change (%) on drug (average vs. baseline)	7.67%	13.99%	0.0072
MSWS-12 change on drug (average) vs. baseline	0.73	-2.62	0.0213
MSWS-12 change Visit 6 vs. baseline	<b>0.83</b>	<b>-2.59</b>	<b>0.0364</b>
SGI change on drug vs. baseline	-0.04	0.09	0.1939
LEMMT change on drug vs. baseline	0.04	0.09	0.1059
Ashworth change on drug vs. baseline	-0.06	-0.18	0.0153